Literature DB >> 28056432

Cadaver study of anchorless implant for the treatment of anterior and apical vaginal wall prolapse.

Mauro Cervigni1, Alfredo Ercoli2, Gil Levy3.   

Abstract

OBJECTIVE: This cadaver study was performed in order to evaluate the feasibility and the anatomical landmarks of a Self-Retaining device, a new unanchored mesh, for the treatment of anterior and apical vaginal prolapse. STUDY
DESIGN: The Self-retaining device was implanted transvaginally in two cadavers. One cadaver underwent a detailed trans-abdominal dissection of the pelvis and the other cadaver, frozen after the implant placement, underwent a cross section dissection of the pelvis.
RESULTS: The location of the device was confirmed to be in appropriate anatomical position and in safe distance from any major neurovascular structures in the pelvis.
CONCLUSION: The self-retaining implant, in its planned location, can be a safe procedure with respect to neighboring neurovascular and muscular pelvic structures. Brief summery: A cadaver study of anchorless implant for safety evaluation of the distance from vital structures. The implant found anatomically safe for use.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cadaver lab; Self-retaining implant; Vaginal mesh

Mesh:

Year:  2016        PMID: 28056432     DOI: 10.1016/j.ejogrb.2016.12.031

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

1.  Self-retaining support implant: an anchorless system for the treatment of pelvic organ prolapse-2-year follow-up.

Authors:  Gil Levy; Anna Padoa; Zoltan Fekete; George Bartfai; Laszlo Pajor; Mauro Cervigni
Journal:  Int Urogynecol J       Date:  2017-07-14       Impact factor: 2.894

2.  Surgical treatment of advanced anterior wall and apical vaginal prolapse using the anchorless self-retaining support implant: long-term follow-up.

Authors:  Gil Levy; Anna Padoa; Naama Marcus; Anat Beck; Zoltan Fekete; Mauro Cervigni
Journal:  Int Urogynecol J       Date:  2022-01-13       Impact factor: 1.932

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.